Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rudanac Biotec Spa is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, reflecting a streamlined prosecution phase for the company's biotech assets. This focused approach indicates that the company is prioritizing a specific biological innovation within its current active filings at the patent office rather than pursuing a broad array of diverse technologies.
The busiest examiner, EMMALEE RAE WILLIAMS, is assigned 1 pending office action. This accounts for the total workload across the portfolio. The concentration in 1 art unit suggests that the company is currently pursuing protection for a specific biological or pharmaceutical innovation, which may simplify the process of navigating the technical requirements and examination standards of that particular unit during the response phase of prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIAMS, EMMALEE RAE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17597328 | METHOD OF BIODESINTEGRATING METAL SCRAP WITH A BACTERIAL CONSORTIUM ADAPTED TO HIGH CONCENTRATIONS OF FERROUS SULPHATE AND FERRIC SULPHATE | WILLIAMS, EMMALEE RAE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17597328 | METHOD OF BIODESINTEGRATING METAL SCRAP WITH A BACTERIAL CONSORTIUM ADAPTED TO HIGH CONCENTRATIONS OF FERROUS SULPHATE AND FERRIC SULPHATE | WILLIAMS, EMMALEE RAE | 1653 | §101§103§112 | Final Rejection | — | Pending | Jan 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRudanac Biotec Spa has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emmalee Rae Williams has the most, with 1 of Rudanac Biotec Spa's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
